Angiotensin-converting enzyme inhibitor for post-transcatheter aortic valve implantation patients: study protocol for a multicenter randomized, open-label blinded endpoint control trial

Table 2 Summary of randomized trials that investigated the effect of renin-angiotensin system blockade therapy after aortic valve replacement for severe aortic stenosis patients

Author, year	Region	Study population	Study design	Registration	Sample size^a	Interventions	Comparison	Primary outcomes	Status
Dahl et al., 2010 [8]	Denmark, single center	Post SAVR	Randomized, open-label, blinded endpoint	NCT00294775	61:64	Candesartan treatment	Conventional treatment	Change in LV mass index	Completed
Amat-Santos et al., 2018 [17]	Spain, 8 centers	Post TAVI	Randomized, open-label, blinded endpoint	NCT03201185	168:168	Ramipril plus standard care	Standard care	Cardiac death or heart failure hospitalization or stroke	Recruiting
Aboyans et al. [18]	France, multicenter	Post SAVR or TAVI	Randomized, quadruple blinded	NCT03315832	55:55	Valsartan	Placebo	Changes in LV mass index	Not yet recruiting
Liao et al.	China, 7 centers	Post TAVI	Randomized, open-label, blinded endpoint	ChiCTR2100042266	100:100	Fosinopril plus standard care	Standard care	Change in LV mass index	Active, not yet recruiting

SAVR surgical aortic valve replacement, LV left ventricle, TAVI transcatheter aortic valve intervention
^aNumber of patients in the intervention group versus the control group

ISSN: 1745-6215